康艾注射液联合化疗治疗晚期胃癌的临床研究

A clinical study of treating advanced gastric cancer with the combination of Kangai injection and chemotherapy

目的：探讨康艾注射液联合化疗在治疗晚期胃癌中的作用。方法：将80例晚期胃癌患者随机分为治疗组（化疗加康艾注射液组）和对照组（单纯化疗组）。观察比较两组细胞免疫功能的变化、近期疗效、生活质量改善和毒副反应。结果：治疗组治疗后NK细胞活性，CD4／CD8比值明显高于治疗前（P〈0．01），CD3、CD4值升高（P〈0．05）。对照组治疗后NK细胞活性，CD3，CD4，CD4／CD8值均较治疗前低（P〈0．05）。治疗组与对照组近期疗效有效率分别为45．5％和40．0％（P〉0．05）。治疗组在白细胞减少、恶心、呕吐、周围神经毒性发生率方面均明显的低于对照组（P〈0．05）。治疗组在乏力减轻、食欲增加、kamfsky增加高于对照组（P〈0．01）。在疼痛减轻、体重增加方面治疗组也高于对照组（P〈0．05）。结论：康艾注射液联合化疔治疗晚期胃癌可降低化疗对患者细胞免疫功能的影响及不良反应，改善患者的生活质量。

Objective ：To explore the effect of treating advanced gastric cancer with the combination of Kangai injection and chemotherapy. Methods ：Eighty patients with advanced gastric cancer were randomly divided into treatment group （chemotherapy ＋ Kangai injection） and control group（chemotherapy only）. Observation was conducted on cellular immunization ,short-term effect ,life quality improvement ,and toxic side-effect in both groups. Results：In the treatment group,both NK cellular activity and CD4/CD8 ratio were higher after the treatment （P〈0. 01）. CD3 and CD4 were both increased（P〈0.05）. In the control group ,the NK cellular activity,CD3,CD4,CD4/CD8 ratio were all lower after the treatment（P〈0.05）. The short-term efficacy rate was 450/oo in the treatment group and 40% in the control group. The difference was not significant. The treatment group was apprarently lower than the control group in leukopenia ,nausea and/vormitting,and peripheral nerve toxicity（P（0. 05）. Compared with the control group ,less fatigue ,better appetite ,and kamotsky increase were observed in the treatment group（P（0. 01）. The treatment group was also observed more effective in relieving pain and gain weight than the control group （P（0. 05）. Conclusion： Treating advance gastric cancer with the combination of Kangai injection and chemotherapy may decrease the negative impact of chemotherapy on patients＇ cellumlar immune functions and other side-effects, therefore, improve the life quality of the patients.